Exelixis (EXEL) to Release Earnings on Thursday

Exelixis (NASDAQ:EXEL) is scheduled to release its earnings data after the market closes on Thursday, November 1st. Analysts expect Exelixis to post earnings of $0.19 per share for the quarter.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.12. Exelixis had a return on equity of 65.68% and a net margin of 48.17%. The business had revenue of $186.10 million during the quarter, compared to analyst estimates of $157.37 million. During the same period in the prior year, the company earned $0.06 earnings per share. Exelixis’s revenue was up 88.0% compared to the same quarter last year. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of NASDAQ EXEL opened at $14.13 on Wednesday. Exelixis has a 1-year low of $13.42 and a 1-year high of $32.20. The firm has a market cap of $4.29 billion, a price-to-earnings ratio of 13.25 and a beta of 1.93.



In related news, CEO Michael Morrissey sold 12,501 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $17.82, for a total value of $222,767.82. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gisela Schwab sold 12,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $17.77, for a total value of $213,240.00. The disclosure for this sale can be found here. Insiders sold 563,629 shares of company stock valued at $11,192,853 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.

Several brokerages have weighed in on EXEL. BidaskClub raised Exelixis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 30th. Guggenheim began coverage on Exelixis in a report on Monday, September 17th. They set a “buy” rating for the company. Stifel Nicolaus reduced their price objective on Exelixis from $29.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, August 1st. ValuEngine lowered Exelixis from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 4th. Finally, Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 price target for the company in a report on Tuesday, July 31st. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Exelixis has an average rating of “Buy” and an average target price of $29.78.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Further Reading: How Do You Make Money With Penny Stocks?

Earnings History for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply